A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
High-grade neuroendocrine cancer is a complex and aggressive condition that has seen few medical advances, in part because its rarity has subdued research investment. Patients have few options beyond conventional chemotherapy.
The new trial, headed by Aman Chauhan, M.D., leader of the Neuroendocrine Tumor Program at Sylvester, offers a fresh approach. Patients will receive a combination of immunotherapy drugs and a tumor-busting “oncolytic” virus injected directly into the tumors.
Tumors in any organ, at any age
Neuroendocrine tumors originate from cells found throughout the body and can affect most…